类风湿关节炎患者接受生物制剂治疗后的机会性感染:来自英国风湿病学会类风湿关节炎生物制剂登记处的结果
该前瞻性观察队列研究纳入19282例开始生物制剂治疗的类风湿关节炎成人患者,随访106347患者年,共识别142例非结核机会性感染,发生率134例/10万患者年。不同药物类别间总体机会性感染发生率无显著差异,但利妥昔单抗组肺孢子菌感染率显著高于抗TNF治疗组(校正HR=3.2,95%CI:1.4,7.5)。结核发生率从2002年783例/10万患者年降至2015年38例/10万患者年,利妥昔单抗组结核发生率显著低于抗TNF组(12例/10万患者年 vs 65例/10万患者年)。
要点
- 不同生物制剂类别间总体机会性感染发生率无显著差异。
- 利妥昔单抗组肺孢子菌感染率显著高于抗TNF组(校正HR=3.2,95%CI:1.4,7.5)。
- 年龄、性别和合并症是机会性感染最重要的预测因素。
核心结论
- 不同药物类别间总体机会性感染发生率无显著差异,但各队列间机会性感染模式存在细微差异。
- 年龄、性别和合并症等患者因素是机会性感染最重要的预测因素。
研究设计与样本
- 英国风湿病学会类风湿关节炎生物制剂登记处是一项前瞻性观察队列研究,旨在评估生物制剂治疗的安全性。
- 研究人群为开始生物制剂治疗的类风湿关节炎成人患者,共纳入19282例患者、106347患者年随访。
- 主要结局为排除结核后的任何严重机会性感染,采用Cox比例风险模型在校正预先识别的潜在混杂因素后比较不同生物制剂类别的事件率。
- 结核发生率分析单独进行。
主要发现
- 共识别142例非结核机会性感染,发生率为134例/10万患者年。
- 不同药物类别间总体机会性感染发生率无显著差异。
- 利妥昔单抗组肺孢子菌感染率显著高于抗TNF治疗组,校正HR=3.2(95%CI:1.4,7.5)。
- 研究期间结核发生率大幅下降,从2002年的783例/10万患者年降至2015年的38例/10万患者年。
- 利妥昔单抗使用者结核发生率显著低于抗TNF使用者,分别为12例/10万患者年 vs 65例/10万患者年。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This analysis set out to estimate the risk of opportunistic infection (OI) among patients with RA by biologic class. METHODS: The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis is a prospective observational cohort study established to evaluate safety of biologic therapies. The population included adults commencing biologic therapy for RA. The primary outcome was any serious OI excluding tuberculosis (TB). Event rates were compared across biologic classes using Cox proportional hazards with adjustment for potential confounders identified a priori. Analysis of the incidence of TB was performed separately. RESULTS: In total, 19 282 patients with 106 347 years of follow-up were studied; 142 non-TB OI were identified at a rate of 134 cases/100 000 patient years (pyrs). The overall incidence of OI was not significantly different between the different drug classes; however, the rate of Pneumocystis infection was significantly higher with rituximab than with anti-TNF therapy (adjusted hazard ratio = 3.2, 95% CI: 1.4, 7.5). The rate of TB fell dramatically over the study period (783 cases/100 000 pyrs in 2002 to 38 cases/100 000 pyrs in 2015). The incidence of TB was significantly lower among rituximab users than anti-TNF users, with 12 cases/100 000 pyrs compared with 65 cases/100 000 pyrs. CONCLUSIONS: The overall rate of OI was not significantly different between drug classes; however, a subtle difference in the pattern of OI was seen between the cohorts. Patient factors such as age, gender and comorbidity were the most important predictors of OI.
引用
- Rutherford AI, Patarata E, Subesinghe S, et al. Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford). 2018. PMID: 29529307. doi:10.1093/rheumatology/key023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。